Published in Cancer Res on June 01, 2005
Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy (2009) 2.71
Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol Ther (2010) 1.55
Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood (2008) 1.31
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J Natl Cancer Inst (2008) 1.28
Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Mol Cancer Ther (2011) 1.18
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem (2009) 1.15
Overexpression of the zinc uptake transporter hZIP1 inhibits nuclear factor-kappaB and reduces the malignant potential of prostate cancer cells in vitro and in vivo. Clin Cancer Res (2008) 1.12
ROCK mediates phorbol ester-induced apoptosis in prostate cancer cells via p21Cip1 up-regulation and JNK. J Biol Chem (2009) 1.10
Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex. Mol Cancer Res (2010) 1.05
Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. Cancer Res (2009) 1.02
Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition. Mol Cell Biol (2014) 0.99
Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts. Cancer Lett (2011) 0.97
The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib. Cancer Res (2008) 0.94
Depletion of intracellular zinc increases expression of tumorigenic cytokines VEGF, IL-6 and IL-8 in prostate cancer cells via NF-kappaB-dependent pathway. Prostate (2008) 0.91
Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. Mol Cancer Ther (2010) 0.90
Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity. Asian J Androl (2012) 0.81
Novel strategies for treating relapsed/refractory urothelial carcinoma. Expert Rev Anticancer Ther (2010) 0.78
Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism. Cell Death Dis (2014) 0.77
Roles of SPARC in urothelial carcinogenesis, progression and metastasis. Oncotarget (2016) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res (2009) 4.19
Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol (2011) 3.19
Focus on bladder cancer. Cancer Cell (2004) 2.59
ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One (2011) 2.49
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res (2005) 2.22
P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol (2007) 2.21
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res (2005) 2.16
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res (2006) 2.15
Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults. Urology (2003) 2.13
Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat (2008) 2.13
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer (2002) 2.12
Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J (2003) 2.11
Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther (2002) 2.03
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood (2007) 1.86
The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol (2008) 1.73
Bax and Bak promote apoptosis by modulating endoplasmic reticular and mitochondrial Ca2+ stores. J Biol Chem (2001) 1.70
Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int (2006) 1.70
Src activation regulates anoikis in human colon tumor cell lines. Oncogene (2002) 1.70
Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer (2007) 1.69
Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology (2006) 1.63
Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther (2004) 1.61
Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res (2004) 1.59
Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol Ther (2010) 1.55
Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res (2008) 1.52
Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res (2003) 1.49
Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection. J Urol (2010) 1.48
Correlation between annual volume of cystectomy, professional staffing, and outcomes: a statewide, population-based study. Cancer (2005) 1.47
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther (2006) 1.45
Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines. Clin Cancer Res (2008) 1.44
Office cystoscopy and transrectal ultrasound-guided prostate biopsies pose minimal risk: prospective evaluation of 921 procedures. Urology (2009) 1.42
Increased apoptosis in metastatic human colonic adenocarcinomas. Cancer Biol Ther (2002) 1.42
Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol (2002) 1.41
Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res (2009) 1.40
Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther (2003) 1.39
The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol (2006) 1.36
Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer (2010) 1.36
Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol (2006) 1.35
Bax-mediated Ca2+ mobilization promotes cytochrome c release during apoptosis. J Biol Chem (2002) 1.35
Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood (2005) 1.34
Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood (2008) 1.31
Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res (2006) 1.30
Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res (2008) 1.30
Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol (2006) 1.27
Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res (2009) 1.25
Cis-urocanic acid, a sunlight-induced immunosuppressive factor, activates immune suppression via the 5-HT2A receptor. Proc Natl Acad Sci U S A (2006) 1.24
Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res (2003) 1.23
Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann Surg Oncol (2011) 1.23
p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One (2012) 1.22
New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. Clin Cancer Res (2011) 1.21
Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol (2007) 1.21
The p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. J Biol Chem (2012) 1.19
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res (2004) 1.19
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol (2002) 1.18
Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol (2003) 1.17
Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther (2007) 1.16
The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res (2010) 1.15
Bladder cancer angiogenesis and metastasis--translation from murine model to clinical trial. Cancer Metastasis Rev (2007) 1.14
Disruption of Mekk2 in mice reveals an unexpected role for MEKK2 in modulating T-cell receptor signal transduction. Mol Cell Biol (2002) 1.12
Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res (2007) 1.11
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res (2005) 1.11
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther (2004) 1.10
Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res (2003) 1.10
Plasma microRNA profiles for bladder cancer detection. Urol Oncol (2012) 1.09
Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther (2002) 1.08
Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer (2014) 1.07
Role of P38 MAPK, AP-1, and NF-kappaB in interleukin-1beta-induced IL-8 expression in human vascular smooth muscle cells. Cytokine (2002) 1.07
Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa. J Urol (2013) 1.06
Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urol Oncol (2003) 1.06
Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res (2011) 1.03
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther (2004) 1.03
The stabilization and targeting of surfactant-synthesized gold nanorods. Nanotechnology (2009) 1.03
Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells. Angiogenesis (2006) 1.03
Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res (2004) 1.02
Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. Clin Cancer Res (2002) 1.02
Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol Cancer Ther (2013) 1.02
Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. Cancer Res (2009) 1.02
Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. Cancer Res (2006) 1.02
The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res (2003) 1.01
Targeted therapies in bladder cancer--an update. Urol Oncol (2007) 1.00
Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol (2004) 1.00
Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis. BJU Int (2010) 0.99
Growth factors and receptors as prognostic markers in urothelial carcinoma. Curr Urol Rep (2008) 0.98